Blood substitutes: how close to a solution?

Harvey G. Klein

Research output: Contribution to journalArticle

Abstract

The term "blood substitute" is commonly misused when "red cell substitute" is meant. The ideal red cell substitute should deliver oxygen (O2), require no compatibility testing, cause few side effects, have prolonged storage qualities, persist in the circulation, and be available at reasonable cost. While no drug with all of these qualities is on the near horizon, several early generation red cell substitutes are approaching submission for licensure, at least for limited indications. Hemoglobin-derived red cell substitutes from human bovine and recombinant sources, as well as perfluorochemicals that dissolve O2, are in different stages of development. While each formulation has its own physical characteristics, biologic activities, and adverse reaction profile, all share one characteristic: The physiologic consequences of delivering O2 with small molecules is poorly understood, both accounting for problems seen in the clinical trials and providing therapeutic opportunities for the cancer patient. All the red cell substitutes in phase II trials have a life measured in hours and are unlikely to replace transfusions or drugs that stimulate erythropoiesis for chronic anemia, but they may play a role in cancer surgery, or even in radiation therapy, or in the management of cancer-related vascular occlusive syndromes.

Original languageEnglish (US)
Pages (from-to)147-151
Number of pages5
JournalOncology
Volume16
Issue number9 Suppl 10
StatePublished - Sep 2002

Fingerprint

Blood Substitutes
Neoplasms
Erythropoiesis
Licensure
Pharmaceutical Preparations
Blood Vessels
Anemia
Hemoglobins
Radiotherapy
Clinical Trials
Oxygen
Costs and Cost Analysis

ASJC Scopus subject areas

  • Oncology

Cite this

Klein, H. G. (2002). Blood substitutes: how close to a solution? Oncology, 16(9 Suppl 10), 147-151.

Blood substitutes : how close to a solution? / Klein, Harvey G.

In: Oncology, Vol. 16, No. 9 Suppl 10, 09.2002, p. 147-151.

Research output: Contribution to journalArticle

Klein, HG 2002, 'Blood substitutes: how close to a solution?', Oncology, vol. 16, no. 9 Suppl 10, pp. 147-151.
Klein HG. Blood substitutes: how close to a solution? Oncology. 2002 Sep;16(9 Suppl 10):147-151.
Klein, Harvey G. / Blood substitutes : how close to a solution?. In: Oncology. 2002 ; Vol. 16, No. 9 Suppl 10. pp. 147-151.
@article{349b6f3fa79741adbce3bcf3c621f78f,
title = "Blood substitutes: how close to a solution?",
abstract = "The term {"}blood substitute{"} is commonly misused when {"}red cell substitute{"} is meant. The ideal red cell substitute should deliver oxygen (O2), require no compatibility testing, cause few side effects, have prolonged storage qualities, persist in the circulation, and be available at reasonable cost. While no drug with all of these qualities is on the near horizon, several early generation red cell substitutes are approaching submission for licensure, at least for limited indications. Hemoglobin-derived red cell substitutes from human bovine and recombinant sources, as well as perfluorochemicals that dissolve O2, are in different stages of development. While each formulation has its own physical characteristics, biologic activities, and adverse reaction profile, all share one characteristic: The physiologic consequences of delivering O2 with small molecules is poorly understood, both accounting for problems seen in the clinical trials and providing therapeutic opportunities for the cancer patient. All the red cell substitutes in phase II trials have a life measured in hours and are unlikely to replace transfusions or drugs that stimulate erythropoiesis for chronic anemia, but they may play a role in cancer surgery, or even in radiation therapy, or in the management of cancer-related vascular occlusive syndromes.",
author = "Klein, {Harvey G.}",
year = "2002",
month = "9",
language = "English (US)",
volume = "16",
pages = "147--151",
journal = "Oncology",
issn = "0890-9091",
publisher = "UBM Medica Healthcare Publications",
number = "9 Suppl 10",

}

TY - JOUR

T1 - Blood substitutes

T2 - how close to a solution?

AU - Klein, Harvey G.

PY - 2002/9

Y1 - 2002/9

N2 - The term "blood substitute" is commonly misused when "red cell substitute" is meant. The ideal red cell substitute should deliver oxygen (O2), require no compatibility testing, cause few side effects, have prolonged storage qualities, persist in the circulation, and be available at reasonable cost. While no drug with all of these qualities is on the near horizon, several early generation red cell substitutes are approaching submission for licensure, at least for limited indications. Hemoglobin-derived red cell substitutes from human bovine and recombinant sources, as well as perfluorochemicals that dissolve O2, are in different stages of development. While each formulation has its own physical characteristics, biologic activities, and adverse reaction profile, all share one characteristic: The physiologic consequences of delivering O2 with small molecules is poorly understood, both accounting for problems seen in the clinical trials and providing therapeutic opportunities for the cancer patient. All the red cell substitutes in phase II trials have a life measured in hours and are unlikely to replace transfusions or drugs that stimulate erythropoiesis for chronic anemia, but they may play a role in cancer surgery, or even in radiation therapy, or in the management of cancer-related vascular occlusive syndromes.

AB - The term "blood substitute" is commonly misused when "red cell substitute" is meant. The ideal red cell substitute should deliver oxygen (O2), require no compatibility testing, cause few side effects, have prolonged storage qualities, persist in the circulation, and be available at reasonable cost. While no drug with all of these qualities is on the near horizon, several early generation red cell substitutes are approaching submission for licensure, at least for limited indications. Hemoglobin-derived red cell substitutes from human bovine and recombinant sources, as well as perfluorochemicals that dissolve O2, are in different stages of development. While each formulation has its own physical characteristics, biologic activities, and adverse reaction profile, all share one characteristic: The physiologic consequences of delivering O2 with small molecules is poorly understood, both accounting for problems seen in the clinical trials and providing therapeutic opportunities for the cancer patient. All the red cell substitutes in phase II trials have a life measured in hours and are unlikely to replace transfusions or drugs that stimulate erythropoiesis for chronic anemia, but they may play a role in cancer surgery, or even in radiation therapy, or in the management of cancer-related vascular occlusive syndromes.

UR - http://www.scopus.com/inward/record.url?scp=0036728935&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036728935&partnerID=8YFLogxK

M3 - Article

C2 - 12380965

AN - SCOPUS:0036728935

VL - 16

SP - 147

EP - 151

JO - Oncology

JF - Oncology

SN - 0890-9091

IS - 9 Suppl 10

ER -